Veradermics Analyst Price Targets - Benzinga

Veradermics Inc

MANENYSE

Trade with Public

Trade with Public

$135.55

-3.23-2.33%

Ult. Agg.: Oct 26, 9:00 AM

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Veradermics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Veradermics (MANE).

Price Target Range — 4 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$157Upside to Avg. PT+15.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 22, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$170→$204
Oct 19, 2026	Cantor Fitzgerald	Prakhar Agrawal	Maintained	Overweight	—
Oct 19, 2026	Needham	Serge Belanger	PT Raise	Buy	$164→$172
Jul 16, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$135→$160
Jul 15, 2026	Needham	Serge Belanger	PT Raise	Buy	$136→$164
Jul 15, 2026	B. Riley Securities	Mayank Mamtani	Initiate	Buy	$170
Jul 7, 2026	Jefferies	Roger Song	PT Raise	Buy	$138→$182
Jun 16, 2026	LifeSci Capital	Rami Katkhuda	Initiate	Outperform	$135
Jun 2, 2026	Needham	Serge Belanger	Initiate	Buy	$136
May 18, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$120→$135
Apr 22, 2026	Leerink Partners	Marc Goodman	PT Raise	Outperform	$75→$90
Mar 2, 2026	Cantor Fitzgerald	Prakhar Agrawal	Initiate	Overweight	—
Mar 2, 2026	Citigroup	Geoff Meacham	Initiate	Buy	$85
Mar 2, 2026	Leerink Partners	Marc Goodman	Initiate	Outperform	$75
Mar 2, 2026	Jefferies	Roger Song	Initiate	Buy	$75

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Veradermics, Raises Price Target to $204

B. Riley Securities analyst Mayank Mamtani maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $170 to $204.

Benzinga Newsdesk

Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday

Analysts upgraded Global-E and raised Annexon’s target; targets fell for Truist, Ameriprise, Lyft, A.O. Smith and Hudson Pacific.

Avi Kapoor

PRO
Cantor Fitzgerald Reiterates Overweight on Veradermicsto Overweight

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Veradermics (NYSE:MANE) from Overweight to Overweight.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Veradermics, Raises Price Target to $172

Needham analyst Serge Belanger maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $164 to $172.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Veradermics, Raises Price Target to $160

Citigroup analyst Geoff Meacham maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $135 to $160.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Veradermics, Raises Price Target to $164

Needham analyst Serge Belanger maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $136 to $164.

Benzinga Newsdesk